ABCL - AbCellera Biologics Inc.
IEX Last Trade
3.03
-0.015 -0.495%
Share volume: 20,047
Last Updated: Thu 26 Dec 2024 08:30:12 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$3.04
-0.02
-0.49%
Fundamental analysis
16%
Profitability
9%
Dept financing
7%
Liquidity
75%
Performance
10%
Performance
5 Days
1.03%
1 Month
4.24%
3 Months
15.23%
6 Months
5.73%
1 Year
-48.87%
2 Year
-71.44%
Key data
Stock price
$3.03
DAY RANGE
$2.89 - $3.06
52 WEEK RANGE
$2.46 - $6.06
52 WEEK CHANGE
-$50.25
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Carl Lars G. Hansen
Region: US
Website: abcellera.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abcellera.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
AbCellera Biologics Inc. has 156 discovery programs that are either completed, in progress, or under contract with 36 partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Recent news